Mobile website
Review
Targeting TLCD1: a novel perspective on tumor lipid metabolism and immunotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] TLC domain containing 1 (TLCD1) is a key rate-limiting enzyme catalyzing the synthesis of phosphatidylethanolamine (PE) from lysophosphatidylethanolamine (LPE), playing a central regulatory role in tumor lipid metabolism reprogramming. TLCD1 is highly expressed in various malignant tumors, affecting tumor proliferation and metastasis through regulating PE synthesis, and is closely associated with poor prognosis. Furthermore, it can reshape the tumor immune microenvironment and promote immune evasion. This review systematically summarizes the molecular mechanisms of TLCD1 in lipid metabolism regulation and immune modulation, explores its potential as a therapeutic target for anti-tumor therapy and as a biomarker for immunotherapy response, providing new insights for optimizing precision tumor treatment strategies.
Keywords:
Project Supported:
Clc Number:
